Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | RAD51C T132P |
Gene Variant Detail | |
Relevant Treatment Approaches | Olaparib |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
RAD51C T132P | Advanced Solid Tumor | sensitive | Olaparib | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, Lynparza (olaparib) treatment resulted in decreased survival of cells expressing RAD51C T132P in culture (PMID: 33832919). | 33832919 |
RAD51C T132P | ovarian cancer | sensitive | Cisplatin + Paclitaxel | Case Reports/Case Series | Actionable | In a clinical case study, treatment with Platinol (cisplatin) plus Taxol (paclitaxel) following surgery resulted in a response with a progression-free survival of at least 10 years in a patient with ovarian cancer harboring RAD51C T132P, and preclinical studies demonstrated cells expressing RAD51C T132P were sensitive to Platinol (cisplatin) in culture (PMID: 33832919). | 33832919 |